Daptomycin for the Treatment of Infections Due to Gram-Positive Bacteria
Daptomycin for the Treatment of Infections Due to Gram-Positive Bacteria
The purpose of this study is to provide daptomycin, an antibiotic, to patients who are
 failing conventional therapy, or who cannot take approved antibiotics for one reason or
 another.
Main Inclusion Criteria:

 -  Infection caused by Staphylococcus aureus, Staphylococcus epidermidis, Enterococcus
 faecalis, or Enterococcus faecium that requires inpatient hospitalization and
 treatment with injectable antibiotics**

 -  Site of infection: complicated skin and skin structure infection; urinary tract
 infection; intra-abdominal infection; infective endocarditis; or bloodstream infection
 (including catheter-related).

 -  Pathogen resistant to, or patient intolerant of: beta-lactams, vancomycin,
 quinupristin/dalfopristin, or linezolid.

 -  Unable to receive any other standard commercially available antibacterial therapy for
 the infection.

 Main Exclusion Criteria:

 -  Creatinine clearance less than 40 mL/min**

 -  Hemodialysis or peritoneal dialysis

 -  Admitted to the hospital for drug overdose or other conditions associated with
 rhabdomyolysis, or is expected to require repeated intramuscular injections

 -  Creatine phosphokinase (CPK) level greater than 2.5 times above the upper limit of
 normal (ULN) at screening; if the elevation in CPK can be attributed to an obvious
 cause (eg, surgery)**

 -  Central nervous system infection

 -  Pulmonary infection.

 (**) An exemption may be granted for patients not satisfying these criteria following a
 conversation with the Medical Monitor.